Infectious Dis. Medical News about Doripenem

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Doripenem
Clinical Infectious Diseases, 06/17/09

Paterson DL - Doripenem is the newest carbapenem to be commercially released. Its antimicrobial spectrum more closely resembles those of meropenem and imipenem than that of ertapenem. Thus, it has significant in vitro activity against streptococci, methicillin-susceptible staphylococci, Enterobacteriaceae (including extended-spectrum beta-lactamase–producing strains), Pseudomonas aeruginosa, Acinetobacter species, and Bacteroides fragilis. Doripenem does not have clinically useful activity against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and the majority of gram-negative bacilli that are resistant to meropenem or imipenem.

<< Previous
Cost of Gestational Diabetes Mellitus in the United States in...

Next >>
The attributable clinical and economic burden of skin and skin...

Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials
Current Medical Research and Opinion, 10/27/09 Relevance Score: 87%

Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation
Current Medical Research and Opinion, 11/13/09 Relevance Score: 84%

In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against Pseudomonas aeruginosa
Antimicrobial Agents and Chemotherapy, 10/08/09 Relevance Score: 80%